With a market cap of $34.5 billion, DexCom, Inc. (DXCM) is a medical device company that designs, develops, and commercializes continuous glucose monitoring (CGM) systems for diabetes and metabolic health management in the United States and internationally. It offers products such as Dexcom G6, Dexcom G7, Dexcom ONE, and Stelo, serving patients, caregivers, and clinicians worldwide.
Shares of the medical device company have underperformed the broader market over the past 52 weeks. DXCM stock has increased 13.8% over this time frame, while the broader S&P 500 Index ($SPX) has returned 20.3%. However, the stock has soared 37.2% on a YTD basis, outpacing SPX's 13.7% gain.